Abstract
Objectives: The aim of the study was to determine whether serum levels of lysylpyridinoline (LP) differ between diabetic foot osteomyelitis (DFO) and diabetic foot ulcers without osteomyelitis (cellulitis). Methods: A case controlled study was designed comparing the aforementioned groups. Subjects were classified as osteomyelitis and controls based on the International Working Group diagnostic criteria. Serum LP samples were analysed using enzyme linked immunosorbent assay. Results: The serum LP levels were significantly higher in the DFO group (n: 16) than the control group (n: 11): LP median ± SD of 9.3 ± 3.5 nmol/l, interquartile range (IQR) 6.8-11.2 in DFO compared to 2.1 nmol/l 3.5, IQR 0.7-4.2 in the controls, p=0.001. The receiver operator characteristic curve in the DFO was 0.9. The diagnostic sensitivity, specificity, positive and negative predictive values were 100%, 77.8%, 89.0% and 100% respectively. Conclusions: This appears to be the first evidence of serum LP elevation in diabetic foot osteomyelitis with potential diagnostic value in clinical setting.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
